Wire · opportunities
FDA approves Novartis' Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
Novartis secured FDA approval for Cosentyx as the first anti-IL-17 biologic treatment for polymyalgia rheumatica in adults with inadequate response or intolerance to corticosteroids, based on positive Phase III trial results. This offers an alternative to long-term steroid use, which carries significant health risks and relapse rates.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
Your drug development just hit a new bar in PMR treatment that reduces steroid reliance. If you target autoimmune diseases, this FDA nod changes competitive standards and clinical expectations right now.
◆ Coverage
3 sources · 17 Nov 2026
◆ Related on Wire
◆ Topics